Regeneron To Acquire Checkmate Pharmaceuticals And Its Investigational Immune Activator For Potential Use In Multiple Tumor Types
Acquiring Company
Regeneron
Acquired Company
Checkmate Pharmaceuticals, Inc.
TarrytownCambridgeBiotechnologyHealth CareScience And EngineeringTherapeuticsBiotechnologyHealthcareHealth CareScience And EngineeringDescription
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.
Who to call at Regeneron, and when
When Regeneron changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Regeneron raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Regeneron, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Regeneron. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Regeneron makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Checkmate Pharmaceuticals, Inc.?
Checkmate Pharmaceuticals, Inc. was acquired by Regeneron, based in Tarrytown. The deal was reported on April 19, 2022. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron is publicly traded (REGN) and operates in Biotechnology.
When did Regeneron acquire Checkmate Pharmaceuticals, Inc.?
Regeneron's acquisition of Checkmate Pharmaceuticals, Inc. was reported on April 19, 2022. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Checkmate Pharmaceuticals, Inc. do?
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.